THOUSAND OAKS, Calif.
March 24, 2014
/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will present pivotal Phase 3 data from five clinical studies evaluating evolocumab (AMG 145), an investigational fully human monoclonal antibody that inhibits PCSK9, a protein that reduces the liver's ability to remove low-density lipoprotein cholesterol (LDL-C), or "bad" cholesterol, from the blood.
The results from the five Phase 3 studies with evolocumab will be presented in three Featured Clinical Research and two Late-Breaking Clinical Trial sessions at the upcoming American College of Cardiology's 63
Annual Scientific Session (ACC.14), being held March 29 – 31 in
To view the multimedia assets associated with this release, please click:
"We are eager to share the detailed findings from our Phase 3 cholesterol-lowering studies of evolocumab at ACC," said
Sean E. Harper
, M.D., executive vice president of Research and Development at Amgen. "The robust data from these studies in more than 4,000 patients form the basis of our global filing plan and we look forward to potentially providing a new treatment option to improve the lives of patients with high cholesterol, who have increased LDL-C levels despite existing therapies."
Among the abstracts are five oral presentations from the large and comprehensive evolocumab clinical trial program, PROFICIO (
educe LDL-C and Cardiovascular
nhibition of P
n Different P
pulations). Data from three Phase 3 studies will be presented in a Featured Clinical Research session on
Saturday, March 29
2 p.m. EDT
and results from two Phase 3 studies will be featured in a Late-Breaking Clinical Trials session on
Sunday, March 30
8 a.m. EDT
Data presented on evolocumab will include: